Stemline Therapeutics Inc (NASDAQ:STML) shot up 5.8% during mid-day trading on Thursday . The stock traded as high as $14.11 and last traded at $14.06. 390,047 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 629,707 shares. The stock had previously closed at $13.29.

Several brokerages have recently issued reports on STML. Roth Capital restated a “buy” rating on shares of Stemline Therapeutics in a research note on Thursday, May 23rd. BidaskClub upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Zacks Investment Research upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. ValuEngine downgraded shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 15th. Finally, Piper Jaffray Companies set a $23.00 price objective on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 18th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $25.20.

The company has a current ratio of 5.07, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million for the quarter, compared to analyst estimates of $2.61 million. As a group, analysts anticipate that Stemline Therapeutics Inc will post -2.14 earnings per share for the current fiscal year.

In related news, COO Kenneth Hoberman sold 25,817 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $14.27, for a total value of $368,408.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.80% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY lifted its position in Stemline Therapeutics by 56.7% in the first quarter. Metropolitan Life Insurance Co NY now owns 13,358 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 4,835 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in Stemline Therapeutics in the first quarter worth $10,050,000. Man Group plc bought a new position in Stemline Therapeutics in the first quarter worth $5,822,000. MetLife Investment Advisors LLC lifted its position in Stemline Therapeutics by 54.6% in the first quarter. MetLife Investment Advisors LLC now owns 18,471 shares of the biopharmaceutical company’s stock worth $237,000 after purchasing an additional 6,524 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Stemline Therapeutics by 3,363.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,363,968 shares of the biopharmaceutical company’s stock worth $17,527,000 after purchasing an additional 1,324,590 shares during the period. 77.66% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/stemline-therapeutics-nasdaqstml-shares-up-5-8/3042681.html.

About Stemline Therapeutics (NASDAQ:STML)

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

See Also: How much money do you need to begin day trading?

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.